Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79


Differential effects of procaspase-3 activating compounds in the induction of cancer cell death.

West DC, Qin Y, Peterson QP, Thomas DL, Palchaudhuri R, Morrison KC, Lucas PW, Palmer AE, Fan TM, Hergenrother PJ.

Mol Pharm. 2012 May 7;9(5):1425-34. doi: 10.1021/mp200673n. Epub 2012 Apr 27.


Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3.

Peterson QP, Hsu DC, Goode DR, Novotny CJ, Totten RK, Hergenrother PJ.

J Med Chem. 2009 Sep 24;52(18):5721-31. doi: 10.1021/jm900722z.


Procaspase-activating compound 1 induces a caspase-3-dependent cell death in cerebellar granule neurons.

Aziz G, Akselsen ØW, Hansen TV, Paulsen RE.

Toxicol Appl Pharmacol. 2010 Sep 15;247(3):238-42. doi: 10.1016/j.taap.2010.07.002. Epub 2010 Jul 16.


ERO1α-dependent endoplasmic reticulum-mitochondrial calcium flux contributes to ER stress and mitochondrial permeabilization by procaspase-activating compound-1 (PAC-1).

Seervi M, Sobhan PK, Joseph J, Ann Mathew K, Santhoshkumar TR.

Cell Death Dis. 2013 Dec 19;4:e968. doi: 10.1038/cddis.2013.502.


Discovery and canine preclinical assessment of a nontoxic procaspase-3-activating compound.

Peterson QP, Hsu DC, Novotny CJ, West DC, Kim D, Schmit JM, Dirikolu L, Hergenrother PJ, Fan TM.

Cancer Res. 2010 Sep 15;70(18):7232-41. doi: 10.1158/0008-5472.CAN-10-0766. Epub 2010 Sep 7.


Targeting procaspase-3 with WF-208, a novel PAC-1 derivative, causes selective cancer cell apoptosis.

Wang F, Liu Y, Wang L, Yang J, Zhao Y, Wang N, Cao Q, Gong P, Wu C.

J Cell Mol Med. 2015 Aug;19(8):1916-28. doi: 10.1111/jcmm.12566. Epub 2015 Mar 8.


Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells.

Zaman S, Wang R, Gandhi V.

Exp Hematol. 2015 Nov;43(11):951-962.e3. doi: 10.1016/j.exphem.2015.07.005. Epub 2015 Aug 6.


Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs.

Lucas PW, Schmit JM, Peterson QP, West DC, Hsu DC, Novotny CJ, Dirikolu L, Churchwell MI, Doerge DR, Garrett LD, Hergenrother PJ, Fan TM.

Invest New Drugs. 2011 Oct;29(5):901-11. doi: 10.1007/s10637-010-9445-z. Epub 2010 May 25.


PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition.

Peterson QP, Goode DR, West DC, Ramsey KN, Lee JJ, Hergenrother PJ.

J Mol Biol. 2009 Apr 24;388(1):144-58. doi: 10.1016/j.jmb.2009.03.003. Epub 2009 Mar 10.


Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma.

Sarkar A, Balakrishnan K, Chen J, Patel V, Neelapu SS, McMurray JS, Gandhi V.

Oncotarget. 2016 Jan 19;7(3):3461-76. doi: 10.18632/oncotarget.6505.


Parallel synthesis and biological evaluation of 837 analogues of procaspase-activating compound 1 (PAC-1).

Hsu DC, Roth HS, West DC, Botham RC, Novotny CJ, Schmid SC, Hergenrother PJ.

ACS Comb Sci. 2012 Jan 9;14(1):44-50. doi: 10.1021/co2001372. Epub 2011 Oct 28.


SM-1, a novel PAC-1 derivative, activates procaspase-3 and causes cancer cell apoptosis.

Chen Y, Sun M, Ding J, Zhu Q.

Cancer Chemother Pharmacol. 2016 Sep;78(3):643-54. doi: 10.1007/s00280-016-3115-6. Epub 2016 Aug 3.


Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells.

Patel V, Balakrishnan K, Keating MJ, Wierda WG, Gandhi V.

Blood. 2015 Feb 12;125(7):1126-36. doi: 10.1182/blood-2014-01-546796. Epub 2014 Dec 23.


Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy.

Putt KS, Chen GW, Pearson JM, Sandhorst JS, Hoagland MS, Kwon JT, Hwang SK, Jin H, Churchwell MI, Cho MH, Doerge DR, Helferich WG, Hergenrother PJ.

Nat Chem Biol. 2006 Oct;2(10):543-50. Epub 2006 Aug 27.


A novel small-molecule activator of procaspase-3 induces apoptosis in cancer cells and reduces tumor growth in human breast, liver and gallbladder cancer xenografts.

Wang F, Wang L, Zhao Y, Li Y, Ping G, Xiao S, Chen K, Zhu W, Gong P, Yang J, Wu C.

Mol Oncol. 2014 Dec;8(8):1640-52. doi: 10.1016/j.molonc.2014.06.015. Epub 2014 Jul 3.


Dual small-molecule targeting of procaspase-3 dramatically enhances zymogen activation and anticancer activity.

Botham RC, Fan TM, Im I, Borst LB, Dirikolu L, Hergenrother PJ.

J Am Chem Soc. 2014 Jan 29;136(4):1312-9. doi: 10.1021/ja4124303. Epub 2014 Jan 16.


Antitumor activity of paclitaxel is significantly enhanced by a novel proapoptotic agent in non-small cell lung cancer.

Razi SS, Rehmani S, Li X, Park K, Schwartz GS, Latif MJ, Bhora FY.

J Surg Res. 2015 Apr;194(2):622-30. doi: 10.1016/j.jss.2014.11.004. Epub 2014 Nov 10.


Cell death induced by novel procaspase-3 activators can be reduced by growth factors.

Boldingh Debernard KA, Aziz G, Gjesvik AT, Paulsen RE.

Biochem Biophys Res Commun. 2011 Sep 23;413(2):364-9. doi: 10.1016/j.bbrc.2011.08.107. Epub 2011 Aug 27.


Synthesis and initial in vitro biological evaluation of two new zinc-chelating compounds: comparison with TPEN and PAC-1.

Strand OA, Aziz G, Ali SF, Paulsen RE, Hansen TV, Rongved P.

Bioorg Med Chem. 2013 Sep 1;21(17):5175-81. doi: 10.1016/j.bmc.2013.06.037. Epub 2013 Jun 26.


Removal of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved Pharmacokinetics.

Roth HS, Botham RC, Schmid SC, Fan TM, Dirikolu L, Hergenrother PJ.

J Med Chem. 2015 May 14;58(9):4046-65. doi: 10.1021/acs.jmedchem.5b00413. Epub 2015 Apr 20.

Supplemental Content

Support Center